Ocular FIP treatment moves further into routine practice

CURRENT FULL VERSION: A new VETgirl podcast on ocular FIP lands at a moment when feline practice has changed in a meaningful way: antiviral treatment for FIP is now supported by a growing clinical literature and, in the U.S., is far more accessible through veterinarian-directed compounding than it was just two years ago. That matters especially for ocular cases, where uveitis, retinal changes, or other eye findings may be among the clearest clues to a disease that was once treated as almost uniformly fatal. The podcast usefully emphasizes that ocular disease can sometimes be the dominant presentation, with signs ranging from keratic precipitates, iris color change, dyscoria, anisocoria, hyphema, hypopyon, and fibrinous anterior chamber exudate to posterior segment lesions such as gray-white fundic changes, retinal hemorrhage, vascular tortuosity, retinal detachment, or perivascular cuffing. (fda.gov)

The background here is important. Early GS-441524 studies established proof of concept for FIP treatment, but severe ocular and neurologic cases were underrepresented in some of the first trials. Since then, the evidence base has broadened through retrospective cohorts, systematic review, and international guideline work. The 2025 ABCD FIP guideline and recent review literature both describe the now-familiar clinical reality: ocular and neurologic involvement often require higher doses, longer or adjusted treatment, and closer follow-up than straightforward effusive disease. That fits with the broader clinical picture highlighted in recent educational coverage: ocular and neurologic signs are seen much more often in non-effusive disease than in classic wet presentations, and some cats present first with eye disease before the rest of the syndrome is fully obvious. (pubmed.ncbi.nlm.nih.gov)

Regulatory and supply changes have also reshaped practice. On May 10, 2024, the FDA said it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat with FIP under the conditions in GFI #256, while also stressing that these compounded products are still unapproved drugs, not formally “legal” approved products. Cornell’s Feline Health Center then highlighted that Stokes Pharmacy, working with Bova, announced U.S. availability of a compounded oral formulation beginning June 1, 2024. By mid-2025, additional pharmacy players, including Wedgewood, had also announced compounded GS-441524 offerings, suggesting the market is becoming more structured, even without an FDA-approved feline product. (fda.gov)

On the clinical side, the signal is fairly consistent even if protocols still vary. A 2025 systematic review found the best outcomes were generally associated with GS-441524 dosages in the 5 to 10 mg/kg once-daily range, adjusted upward for disease type, severity, and neurologic or ocular signs, with divided dosing sometimes used to address absorption concerns. The ABCD guideline goes further, noting that remdesivir doses up to 20 mg/kg every 24 hours, administered as 10 mg/kg every 12 hours, may be indicated for ocular or neurologic FIP. A newer Scientific Reports analysis likewise concluded that GS-441524 can be a viable option for surviving ocular and neurologic FIP when dosing is sufficient. Recent VETgirl discussion of dosing and duration adds another practical wrinkle: the traditional 12-week course remains the default, but investigators are now asking whether higher-dose induction protocols might reduce viral burden faster and eventually support shorter treatment in selected cases, especially if clinicians use objective stopping criteria rather than appearance alone. (pubmed.ncbi.nlm.nih.gov)

There’s also a growing body of case-level and cohort evidence behind the discussion. One published case report described successful treatment of a cat with ocular FIP using an oral drug containing GS-441524 after fulminant anterior uveitis. A retrospective JVIM study of cats treated with remdesivir, GS-441524, or both specifically tracked ocular and neurologic presentations and used structured diagnostic review aligned with ABCD guidance. That’s not the same as having large randomized trials in ocular FIP specifically, but it does show the field moving from anecdote toward more standardized clinical evidence. The VETgirl podcast on the Royal Veterinary College series helps translate that literature into exam-room relevance by focusing on how these cats actually present and respond in practice, rather than treating ocular FIP as a rare footnote. (pubmed.ncbi.nlm.nih.gov)

Industry and expert commentary has followed the same arc: cautious optimism, with repeated warnings about product quality, dose selection, and diagnostic rigor. Cornell described the U.S. availability of compounded GS-441524 as a major advance for a previously untreatable disease, while the FDA emphasized guardrails around compounding. Meanwhile, published quality assessments of unregulated antiviral products have underscored why veterinarians prefer pharmacy-based, veterinarian-prescribed channels over black-market sourcing whenever possible. That same practical caution shows up in clinician education around diagnosis: even with treatment success rates now often cited in the 85% to 90% range, FIP is still usually a presumptive diagnosis in practice, built from signalment, clinicopathologic changes, imaging or effusion findings, and compatible ocular, neurologic, or systemic disease rather than a single easy confirmatory test. (fda.gov)

Why it matters: For veterinarians, the practical takeaway is that ocular FIP should increasingly trigger a treatment conversation, not just a prognosis discussion. The challenge is that these cases can sit at the intersection of internal medicine, ophthalmology, and, at times, neurology. That means practices need workflows for recognizing suspicious ocular findings, discussing presumptive versus definitive diagnosis with pet parents, choosing an antiviral protocol that reflects ocular involvement, and monitoring response with repeat exams and clinicopathologic data. The evidence base now supports intervention, but it also suggests that underdosing ocular cases is a real risk. Just as important, newer discussion around treatment duration is pushing clinicians away from relying only on “the cat looks better”: many cats improve within days to a week, but objective markers such as serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin trends may prove more useful for deciding when therapy can safely stop. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase will likely be less about whether ocular FIP is treatable and more about standardizing how it’s treated, including oral versus injectable strategies, when to split doses, how long to treat beyond clinical resolution, and which monitoring markers best predict relapse or durable remission. Until an FDA-approved veterinary product arrives, compounded prescribing policy, pharmacy participation, and guideline updates will continue to shape how quickly cats reach treatment in general practice and referral settings. Expect more attention, too, on practical diagnostic cues from real-world cases, since earlier recognition of ocular-predominant disease may be one of the biggest determinants of whether cats get to treatment before inflammation becomes harder to reverse. (fda.gov)